Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | beta catenin | 0.0203 | 0.0031 | 0.5 |
Onchocerca volvulus | Cirhin homolog | 0.0202 | 0 | 0.5 |
Loa Loa (eye worm) | HMP-2 protein | 0.0203 | 0.0031 | 0.5 |
Brugia malayi | Armadillo/beta-catenin-like repeat family protein | 0.0203 | 0.0031 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0494 | 0.6851 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 6.65 % | Analgesic activity in Mus musculus balb/cj (mouse) assessed as preference to open arm at 30 mg/kg, ip measured after 30 min by elevated pluze maze test | ChEMBL. | No reference |
Activity (functional) | = 10.06 % | Antidepressant activity in Mus musculus (mouse) assessed as increase in mobile phase at 30 mg/kg, ip measured after 30 min by tail suspension test | ChEMBL. | No reference |
Inhibition (functional) | = 25.22 % | Antidepressant activity in Mus musculus (mouse) assessed as decrease in immobility at 30 mg/kg, ip measured after 30 min by despair swim test | ChEMBL. | No reference |
TIME (functional) | = 26.64 s | Analgesic activity in Mus musculus balb/cj (mouse) assessed as time spent in open arm at 30 mg/kg, ip measured after 30 min by elevated pluze maze test (Rvb = 12.25 +/- 0.02 sec) | ChEMBL. | No reference |
Time (functional) | = 133.2 s | Analgesic activity in Mus musculus Swiss (mouse) assessed as time spent in light chamber at 30 mg/kg, ip measured after 30 min by light and dark model test (Rvb = 130.2 +/- 0.01 sec) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.